Journal
Spotlights
Webinars
Channels
Analytics
Manufacturing
Vectors
Regulatory
Supply Chain
Translational Research & Clinical Development
Business and Finance
Reports
Regulatory Insights
Clinical Trends
Innovation Insights
Business Insights
Investor Insights
FastFacts
Media Kit
Media Kit
Editorial calendar
Sponsorship opportunities
Webinars
About
Submit your manuscript
Meet the team
Get in touch
Immuno-Oncology Insights
Login
Register
Update your profile
Logout
CELL & GENE THERAPY
INSIGHTS
New horizons in cellular immunotherapy: next-gen platforms and modalities
Guest Editor:
David Morrow, Scientific Programme Manager, Translational Medicine & Drug Development at EATRIS
David Morrow
Scientific Programme Manager, Translational Medicine & Drug Development at EATRIS
October 2020
Sponsor
Download full spotlight
Temferon™, an
ex-vivo
genetically modified cell therapy aiming to fill the gaps for solid tumor immunotherapy
S Mazzoleni,
B Gentner,
V Brambilla
et al.
13 November 2020
Expert Insight
Read more
Evolving the role of gene editing in cell therapy
J Frampton,
T Meissner,
T Thwaites
29 October 2020
Innovator Insight
Read more
Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy
R Firdessa-Fite,
J Postigo-Fernandez,
V Toussaint-Moreau
et al.
29 October 2020
Innovator Insight
Read more
The progression & delivery of adoptive cellular immune therapies: leveraging single-cell resolution & novel algorithms to overcome the challenges associated with allogeneic & autologous immune cell therapies
V Moignard,
A De Riva,
R Elgueta
29 October 2020
Innovator Insight
Read more
Engineering precision cell therapy for immune-mediated disease
M Milone,
G Binder
27 October 2020
Expert Insight
Read more
FDA perspective on the preclinical development of cell-based immunotherapies
A Kosmides Galaro,
C Saeui
23 October 2020
Regulatory Insight
Read more
Driving lupus out with CARs
M Radic
22 October 2020
Interview
Read more
Developing harmonized immune platforms: a must-have for realizing personalized therapies in solid tumors
D Morrow,
J Langermans,
A Ussi
et al.
20 October 2020
Commentary
Read more
From a clinician’s perspective: road to safer CAR-T cell immunotherapies
C Li,
H Mei
20 October 2020
Expert Insight
Read more
Immunological tolerance: scanning a barren landscape for signs of sustained growth
H Petropoulos,
T Davies,
P Fairchild
28 September 2020
Expert Insight
Read more
Is a second wave of (CAR T) cell based cancer therapies a mirage or reality?
D Gilham
22 September 2020
Commentary
Read more
Evolving the role of gene editing in cell therapy
Jonathan Frampton, Horizon Discovery at Horizon Discovery
Tristan Thwaites, Lead Technical Scientist at Cell and Gene Therapy Catapult
Torsten Meissner, Postdoctoral Fellow, Department of Stem Cell & Regenerative Biology at Harvard Medical School
6 October 2020
Webinar
Watch now
×
Please enter your email to register
Register